Alnylam (ALNY) Tops Q4 EPS by 28c but Revenue Falls Short, Offers Guidance

February 7, 2013 4:12 PM

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q4 EPS of ($1.20), $0.28 better than the analyst estimate of ($1.48). Revenue for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found